Ranolazine
Brand names: Ranolazine Er
At a glance
- Medicare prescriptions, 2024
- 953,877
- Medicare drug cost
- $83.4M
- Average cost per prescription
- $87.39
- Clinicians who prescribed it
- 26,135
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Ranolazine extended-release tablets are indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
From the FDA-approved prescribing information (label dated May 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Cardiology 38.9%
- Interventional Cardiology 17.8%
- Nurse Practitioners 15.8%
- Internal Medicine 10.4%
- Family Medicine 8.2%
- Physician Assistants 4.6%
- Cardiac Electrophysiology 1.2%
- Geriatric Medicine 0.7%
- General Practice 0.6%
- Heart Failure & Transplant Cardiology 0.5%
- Hospitalist 0.3%
- Nuclear Medicine 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 8% from 2019 to 2024.
Biggest change by state since 2019
- Washington +48%
- Wisconsin +44%
- Puerto Rico +41%
- Alabama +38%
- Arkansas +32%
- New York (smallest change) −15%
- New Jersey (smallest change) −14%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | orange oval tablet, 17 mm | RZ1 |
Lifestar Pharma LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | white oval tablet, 17 mm | LS 703 |
| 1000 mg | yellow oval tablet, 21 mm | LS 704 |
Major Pharmaceuticals
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | orange oval tablet, 17 mm | A47 500 |
Umedica Laboratories USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | yellow oval tablet, 17 mm | RAN500 |
| 1000 mg | yellow oval tablet, 22 mm | RAN1000 |
Zydus Lifesciences Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 500 mg | orange oval tablet, 17 mm | 588 |
| 1000 mg | yellow oval tablet, 22 mm | 589 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
3 recalls since 2020
- Sep 2026 · Ajanta Pharma USA Inc · Class II
Failed Dissolution Specifications: below specification - Mar 2025 · Glenmark Pharmaceuticals Inc., USA · Class II
CGMP Deviations - Oct 2023 · Glenmark Pharmaceuticals Inc., USA · Class II
Failed Dissolution Specifications: Out of specification for dissolution.
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.